Quick Answer
KalVista Pharmaceuticals, Inc. reported Diluted EPS of $3.69 per share (loss) for fiscal year 2025.
KalVista Pharmaceuticals, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$3.69 | -7.3% |
| 2024 | -$3.44 | -3.3% |
| 2023 | -$3.33 | +0.9% |
| 2022 | -$3.36 | -38.8% |
| 2021 | -$2.42 | -47.6% |
| 2020 | -$1.64 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.92 | -9.5% | +17.9% |
| July 31, 2025 | -$1.12 | -28.7% | -21.7% |
| January 31, 2025 | -$0.92 | -9.5% | -1.1% |
| October 31, 2024 | -$0.91 | -13.7% | -8.3% |
| September 30, 2024 | -$0.84 | — | +3.4% |
| July 31, 2024 | -$0.87 | -17.6% | -3.6% |
| January 31, 2024 | -$0.84 | -12.0% | -5.0% |
| October 31, 2023 | -$0.80 | +11.1% | -8.1% |
- KalVista Pharmaceuticals, Inc. showed a decrease of -7.3% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, KalVista Pharmaceuticals, Inc.’s diluted eps has declined by 125.0% (from $1.64 per share (loss) to $3.69 per share (loss)).
- The most recent figure is from KalVista Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on July 10, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: